MELISSA GIONFRIDDO: Open Payments
NPI 1154553956 · MADISON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,729 in 84 payments from 17 companies in 2025. Trend: 2023 $1,632 · 2024 $1,561 · 2025 $1,729
Food & beverage: $1,729
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $448 |
| Novo Nordisk Inc | 9 | $180 |
| GlaxoSmithKline, LLC. | 10 | $166 |
| Lilly USA, LLC | 6 | $157 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $127 |
| Astellas Pharma US Inc | 5 | $126 |
| Amgen Inc. | 4 | $73 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| Exact Sciences Corporation | 2 | $52 |
Products named: VRAYLAR, MOUNJARO, UBRELVY, REXULTI, TRELEGY ELLIPTA, FANAPT, Veozah, Wegovy.
Industry payments across CT — which companies pay providers there.
